News

Research – TherapeuticsMD (TXMD) – First quarter 2019 earnings update

Health
0 min read

Tuesday, May 7, 2019

TherapeuticsMD (TXMD)

Will Revenue Trends From Imvexxy be Recognized?

TherapeuticsMD Inc is a major drug manufacturing with a focus on creating and commercializing products targeted exclusively for women. The company intends to commercialize advanced hormone therapy pharmaceutical products. 

Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.

Refer to full report for price target, fundamental analysis and rating.

  • Solid Imvexxy
    Revenue Growth. 
    Net revenue generated by Imvexxy reached $2.0 million in Q1 2019 (+122%) compared to $0.9 in the fourth quarter of 2018 with sustained growth in prescription and refill rates; approximately 31,200 prescriptions in April 2019 (47,500 prescriptions in Q4 2018). In our view, increasing market share of Imvexxy will be meaningful to eradicate skepticism on commercialization.
  • Bijuva Launch to Follow
    with Annovera. 
    Annovera is set to launch in Q3 2019, following Bijuva’s launch in April 2019. We continue to highlight the market and cost synergies of Bijuva and Imvexxy, and also no…






Get full report on Channelchek desktop.

*Analyst
certification and important disclosures included in full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

Share

Inbox Intel from Channelchek.

Informed investors make more money. And it’s all about timing. Get it when it happens.

By clicking submit you are agreeing to the Terms of Use and Privacy Policy
© 2018-2024 Noble Financial Group, Inc. All Rights Reserved. Channelchek is provided at no cost to be used for information purposes only and not as investment advisement.